Protein Summary
Could act as a modulator of transcription. The product of this gene belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneous humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. While some of the related SSX genes are involved in t(X;18)(p11.2;q11.2) translocations that are characteristically found in all synovial sarcomas, this gene does not appear to be involved in such translocations. Two transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Jul 2013]
- ENST00000311798
- ENSP00000312415
- ENSG00000165583
- ENST00000347757
- ENSP00000290558
- ENST00000376923
- ENSP00000366122
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
protein domain | 0.58 | ||
cell line | 0.45 | ||
biological process | 0.41 | ||
microRNA | 0.4 | ||
tissue | 0.39 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1.81 (req: < 5)
Gene RIFs: 1 (req: <= 3)
Antibodies: 256 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1.81 (req: >= 5)
Gene RIFs: 1 (req: > 3)
Antibodies: 256 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 2
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0